Tafluprost Eye Drops Uses, Dosage, Side Effects & Price | DrugsAtlas
Authoritative Clinical Reference
Navigation
DRUG NAME: Tafluprost
Therapeutic Class: Prostaglandin F2α Analogue
Subclass: Antiglaucoma Agent
Speciality: Ophthalmology
Schedule (India): Schedule H (Prescription Drug)
Route(s): Ophthalmic (topical)
Formulations Available in India:
- Eye drops: 0.0015% w/v ophthalmic solution (preservative-free, single-dose units)
INDICATIONS + DOSING — FOR CLINICIAN USE ONLY
Primary Indications (Approved / Standard in India)
1. Open-Angle Glaucoma
| Parameter | Recommendation |
| Starting dose | 1 drop of 0.0015% solution into affected eye(s) once daily in the evening |
| Titration | Not applicable |
| Usual maintenance dose | 1 drop once daily in the evening |
| Maximum dose | Once daily only — more frequent administration may paradoxically reduce IOP-lowering efficacy |
2. Ocular Hypertension
| Parameter | Recommendation |
| Starting dose | 1 drop of 0.0015% solution into affected eye(s) once daily in the evening |
| Titration | Not applicable |
| Usual maintenance dose | 1 drop once daily in the evening |
| Maximum dose | Once daily only |
Clinical Notes (Both Indications):
- Onset of action: 2–4 hours; peak IOP reduction at 12–24 hours
- Full therapeutic effect may require up to 4 weeks of consistent use
- Preservative-free formulation is preferred for patients with ocular surface disease, chronic dry eye, or benzalkonium chloride sensitivity
- Discard single-dose unit immediately after use; do not store opened units
- If using multiple topical ophthalmic agents, maintain minimum 5-minute interval between drops
Secondary Indications — Adults (Off-label, if any)
Not established in Indian clinical practice.
PAEDIATRIC DOSING (Specialist Only)
Primary Indications
Not recommended for use in patients below 18 years — insufficient safety and efficacy data in paediatric population.
Secondary Indications — Paediatric Doses (Off-label, if any)
| Indication | Dose | Notes |
| Juvenile open-angle glaucoma | 1 drop once daily in the evening |
OFF-LABEL — Specialist ophthalmologist supervision mandatory
|
⚠️ Safety Monitoring (if used off-label):
- Regular IOP measurements
- Monitor for iris pigmentation changes
- Observe for eyelash changes and periorbital effects
- Watch for signs of ocular inflammation
Evidence basis: Limited international case series; no Indian paediatric data available.
RENAL ADJUSTMENT
No dose adjustment required — negligible systemic absorption via ophthalmic route.
HEPATIC ADJUSTMENT
| Severity | Recommendation |
| Mild impairment | No adjustment required |
| Moderate impairment | No adjustment required |
| Severe impairment | Use with caution — limited pharmacokinetic data; specialist discretion advised |
CONTRAINDICATIONS
- Hypersensitivity to tafluprost or any excipient in the formulation
- Active uveitis or intraocular inflammation
- History of recurrent iritis/uveitis
CAUTIONS
- Aphakic patients — increased risk of cystoid macular oedema
- Pseudophakic patients with torn posterior lens capsule — macular oedema risk
- History of herpetic keratitis — potential for reactivation
- History of intraocular inflammation — may exacerbate
- Risk factors for cystoid macular oedema (diabetic retinopathy, retinal vein occlusion, prior vitrectomy)
- Patients with mixed-colour irides — gradual, potentially irreversible iris pigmentation may occur
- Concurrent use of contact lenses — although preservative-free, wait 15 minutes before lens insertion as precaution
PREGNANCY
| Parameter | Recommendation |
| Risk category | Not recommended; animal studies indicate reproductive toxicity |
| Preferred alternatives | Timolol eye drops (if systemic beta-blockade acceptable); Brimonidine (second-line) |
| When permissible | Only if potential benefit justifies fetal risk; specialist ophthalmology input essential |
| Monitoring | Fetal growth surveillance if exposure occurs during pregnancy |
LACTATION
| Parameter | Recommendation |
| Compatibility | Likely compatible — minimal systemic absorption from topical ocular use |
| Drug levels in milk | Expected to be negligible |
| Preferred alternative | Timolol eye drops |
| Infant monitoring | Observe for feeding difficulties, excessive sleepiness, irritability |
ELDERLY
- No dose adjustment required
- May have increased sensitivity to local ocular adverse effects (irritation, hyperaemia)
- Monitor for ocular surface changes, especially in those with pre-existing dry eye
- Assess adherence — single-dose units may require dexterity for proper use
- Regular IOP monitoring recommended
MAJOR DRUG INTERACTIONS
| Interacting Drug | Effect | Recommendation |
| Other prostaglandin analogues (latanoprost, bimatoprost, travoprost) | Paradoxical IOP elevation or reduced efficacy | Avoid concurrent use |
| Topical corticosteroids (ophthalmic) | May significantly reduce IOP-lowering effect | Avoid if possible; if essential, monitor IOP closely |
MODERATE DRUG INTERACTIONS
| Interacting Drug | Effect | Recommendation |
| Topical NSAIDs (ophthalmic) | May blunt prostaglandin-mediated IOP reduction | Monitor IOP response |
| Systemic prostaglandin inhibitors (e.g., high-dose NSAIDs) | Theoretical reduction in ocular response | Limited evidence; monitor if concern arises |
COMMON ADVERSE EFFECTS
- Conjunctival hyperaemia
- Ocular stinging or burning upon instillation
- Eye pruritus
- Increased eyelash length, thickness, and pigmentation
- Iris pigmentation (gradual)
- Dry eye sensation
- Foreign body sensation
- Eyelid skin darkening
SERIOUS ADVERSE EFFECTS
- Cystoid macular oedema — particularly in aphakic/pseudophakic patients; discontinue immediately and refer
- Uveitis or iritis — requires temporary or permanent discontinuation
- Herpetic keratitis reactivation — discontinue and avoid future prostaglandin analogue use
- Prostaglandin-associated periorbitopathy (PAP) — deepening of upper lid sulcus, periorbital fat atrophy with prolonged use
MONITORING REQUIREMENTS
| Timing | Parameters |
| Baseline | IOP measurement, complete ocular examination, iris colour documentation, fundus evaluation |
| 2–4 weeks post-initiation | IOP response assessment, tolerability evaluation |
| Every 3–6 months | IOP, ocular surface health, visual acuity, iris colour comparison |
| Annually | Comprehensive examination including OCT for macular oedema (especially in at-risk patients), eyelash/eyelid/periorbital changes |
BRANDS AVAILABLE IN INDIA
Single-agent formulations:
- Taflotan® (Santen/Dr. Reddy’s)
Note: Limited brand availability in India compared to other prostaglandin analogues. Verify current availability with local distributors.
PRICE RANGE (INR)
| Formulation | Price Range |
| Tafluprost 0.0015% preservative-free (30 single-dose units/month supply) | ₹2,500–₹4,000 per month |
Note:
- Significantly higher cost compared to preserved prostaglandin analogues (latanoprost, travoprost)
- Not included in NLEM; not under NPPA price control
- Cost-effectiveness consideration important when prescribing
CLINICAL PEARLS
- Evening dosing optimises efficacy — instill at bedtime for best IOP control and reduced perception of transient hyperaemia
- Preservative-free advantage — preferred choice for patients with ocular surface disease, chronic dry eye, or benzalkonium chloride intolerance
- Do not combine with other prostaglandin analogues — no additive benefit; may reduce efficacy
- Warn patients about permanent iris colour change — particularly important in heterochromic irides or unilateral treatment
- Periorbital changes are cumulative — counsel patients regarding possible deepening of lid sulcus with long-term use
- Higher cost limits use — reserve for patients who cannot tolerate preserved formulations; consider cost when choosing first-line agent
TAGS
tafluprost; glaucoma; prostaglandin-analogue; ocular-hypertension; preservative-free; ophthalmology; iris-pigmentation; NLEM-absent; ocular-surface-disease
VERSION
RxIndia v1.0 — 03 Feb 2026
REFERENCES
- CDSCO-approved product information
- Indian Pharmacopoeia / National Formulary of India
- AIIMS Ophthalmology Department Treatment Protocols
- API Textbook of Medicine
- Indian Journal of Ophthalmology consensus recommendations
- Santen Prescribing Information (India)
- WHO Essential Medicines List (supportive reference only)
⚖️
Clinical Responsibility
This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.
Content Feedback
Is this information helpful?
Help us improve our clinical database for the medical community.